Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 168 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EBV Clear all
Completed Phase 1 Interventional

Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)

NCT00058591
View directory record Official record
Conditions
Epstein-Barr Virus Infections
Interventions
Intravenous injection of EBV specific CTLS
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 10:49 PM EDT
Terminated Not applicable Interventional Results available

Metabolic and Microbial Profiling of Lung Cancer

NCT03998189
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer Stage
Interventions
Breath Collection, Saliva Collection, Blood Collection, Urine Collection, Tumor Collection, Medical History Data Collection
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 30, 2026, 10:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

NCT03397706
View directory record Official record
Conditions
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
Interventions
VRx-3996 and valganciclovir
Combination Product
Lead sponsor
Viracta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 30, 2026, 10:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations

NCT00070785
View directory record Official record
Conditions
Epstein-Barr Virus Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 10:49 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas

NCT03586024
View directory record Official record
Conditions
Lymphoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 30, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

NCT00297206
View directory record Official record
Conditions
Herpes Simplex
Interventions
Valaciclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Month to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 30, 2026, 10:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

NCT00141037
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 30, 2026, 10:49 PM EDT
Recruiting Phase 2 Interventional

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

NCT05934448
View directory record Official record
Conditions
Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory, Primary Mediastinal Large B-Cell Lymphoma Recurrent, Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion, Leukapheresis
Drug · Procedure
Lead sponsor
Jennifer Crombie, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 30, 2026, 10:49 PM EDT
Completed Phase 1Phase 2 Interventional

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

NCT05683834
View directory record Official record
Conditions
Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions
Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 10:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epstein-Barr Virus as a Possible Cause for Chronic Fatigue Syndrome

NCT00433355
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Mar 19, 2009 · Synced Oct 30, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)

NCT00516087
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Genetically modified CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 30, 2026, 10:49 PM EDT
Terminated Phase 1 Interventional

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

NCT02231853
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, CML (Chronic Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), Acute Lymphoblastic Leukemia, AML (Acute Myelogenous Leukemia)
Interventions
MVST, MVSTr
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 10:49 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 30, 2026, 10:49 PM EDT
Terminated Phase 1 Interventional Results available

Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD

NCT00278200
View directory record Official record
Conditions
Lymphoproliferative Disorder
Interventions
Inactivated EBV-infected vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 30, 2026, 10:49 PM EDT
Withdrawn Phase 1 Interventional

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

NCT04952584
View directory record Official record
Conditions
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Interventions
CD30.CAR-EBVST cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 30, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

NCT00006340
View directory record Official record
Conditions
Leukemia, Lymphoma, Precancerous Condition, Small Intestine Cancer
Interventions
arginine butyrate, ganciclovir
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 30, 2026, 10:49 PM EDT
Recruiting Not applicable Interventional

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

NCT06682442
View directory record Official record
Conditions
Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Cancer, Nasopharyngeal Cancer Stage
Interventions
Intensity-Modulated Radiation Therapy (IMRT), Radiographic Imaging, Biospecimen Collection
Radiation · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

NCT02285062
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 10:49 PM EDT
Terminated Phase 1 Interventional Results available

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

NCT05166577
View directory record Official record
Conditions
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
Interventions
Nanatinostat, Valganciclovir, Pembrolizumab
Drug
Lead sponsor
Viracta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 30, 2026, 10:49 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

NCT03769467
View directory record Official record
Conditions
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia, Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Interventions
Tabelecleucel, Pembrolizumab
Biological
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Duarte, California • Palo Alto, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 30, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib Plus Rituximab for EBV+ PTLD

NCT01058239
View directory record Official record
Conditions
Post-transplant Lymphoproliferative Disease, Solid Organ Transplant, Stem Cell Transplant (Bone Marrow Transplant), Epstein Barr Virus Infections
Interventions
bortezomib, rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 30, 2026, 10:49 PM EDT
Recruiting Not applicable Interventional

PATCHVALVE: Endobronchial Valves Plus Blood Patch for Persistent Air Leaks

NCT07184528
View directory record Official record
Conditions
Persistent Air Leaks
Interventions
Endobronchial Blood Patch, Spiration Valve System (SVS) Placement
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 30, 2026, 10:49 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

NCT05305040
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions
Posoleucel (ALVR105), Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 30, 2026, 10:49 PM EDT
No Longer Available No phase listed Expanded access

Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)

NCT01945619
View directory record Official record
Conditions
EBV Infection, CMV Infection, Adenoviral Infection
Interventions
Trivirus-Specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 30, 2026, 10:49 PM EDT